Cargando…

Understanding the biology and use of anti-TNF agents in JIA – interim results

Detalles Bibliográficos
Autores principales:	Lovell, Daniel J, Spalding, Steven P, Onel, Karen, Gottlieb, Beth S, Brunner, Hermine I, Kimura, Yukiko, Morris, Paula W, Olson, Judyann C, Johnson, Anne, Giannini, Edward H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3402964/ http://dx.doi.org/10.1186/1546-0096-10-S1-A48

Ejemplares similares

Understanding the biology and use of TNF therapy in jia-clinical outcomes
por: Lovell, Daniel, et al.
Publicado: (2014)

The effects of early aggressive therapy in JIA: results of the TREAT study
por: Wallace, Carol A, et al.
Publicado: (2012)

High levels of DEK autoantibodies may predict early flare following cessation of anti-TNF therapy in juvenile idiopathic arthritis
por: Mor-Vaknin, Nirit, et al.
Publicado: (2014)

High Levels of DEK Autoantibodies in Sera of Patients With Polyarticular Juvenile Idiopathic Arthritis and With Early Disease Flares Following Cessation of Anti–Tumor Necrosis Factor Therapy
por: Mor‐Vaknin, Nirit, et al.
Publicado: (2018)

Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry Seven‐Year Interim Results
por: Brunner, Hermine I., et al.
Publicado: (2020)

Land-Jump Performance in Patients with Juvenile Idiopathic Arthritis (JIA): A Comparison to Matched Controls
por: Ford, Kevin R., et al.
Publicado: (2009)

DNase I levels in JIA – influence of anti-TNF (etanercept) therapy
por: Vojinovic, J, et al.
Publicado: (2008)

Demographic, clinical and treatment characteristics of the carra registry systemic JIA cohort
por: Janow, Ginger, et al.
Publicado: (2014)

Anakinra in systemic juvenile idiopathic arthritis (soJIA) non responsive to antiTNF
por: Pontikaki, I, et al.
Publicado: (2008)

PReS-FINAL-2002: Adverse events during anti-TNF therapy in patients with JIA
por: Tarkiainen, M, et al.
Publicado: (2013)

Epidemiology of JIA
por: Lahdenne, Pekka
Publicado: (2014)

The effects of TNF-alpha inhibitor therapy on the incidence of infection in JIA children: a meta-analysis
por: Nagy, Arnold, et al.
Publicado: (2019)

Safety of celecoxib and nonselective nonsteroidal anti-inflammatory drugs in juvenile idiopathic arthritis: results of the phase 4 registry
por: Sobel, Rachel E, et al.
Publicado: (2014)

PReS-FINAL-2139: Tapering and withdrawal of tocilizumab in patients with systemic JIA in inactive disease: results from an alternative dosing regimen in the tender study
por: De Benedetti, F, et al.
Publicado: (2013)

PReS-FINAL-2159: Tocilizumab (TCZ) dosing in juvenile idiopathic arthritis (JIA): optimising for different JIA type and body weight patients
por: Lu, P, et al.
Publicado: (2013)

Abatacept for severe anti-TNF-alfa refractory JIA-associated uveitis: one year follow-up
por: Alpigiani, MG, et al.
Publicado: (2011)

JIA pathogenesis - genetics
por: Thomson, Wendy
Publicado: (2014)

Response to Jia and Wang
por: Liu, Xu, et al.
Publicado: (2020)

PReS13-SPK-1137: New developments in our care & understanding of JIA
por: Beresford, MW
Publicado: (2013)

PReS13-SPK-1478: New developments in our care & understanding of JIA
por: Wedderburn, L
Publicado: (2013)

Efficacy and safety of tocilizumab (TCZ) in patients with systemic juvenile idiopathic arthritis (sJIA): TENDER 52-week data
por: De Benedetti, Fabrizio, et al.
Publicado: (2012)

Efficacy of a second TNF blocker, when the first one failed, in patients with juvenile idiopathic arthritis (JIA)
por: Salmaso, A, et al.
Publicado: (2008)

Predictors of response in patients with active systemic JIA (SJIA) receiving canakinumab: an exploratory analysis of pooled 12-week data
por: Ruperto, N, et al.
Publicado: (2014)

Broadening our understanding of the genetics of Juvenile Idiopathic Arthritis (JIA): Interrogation of three dimensional chromatin structures and genetic regulatory elements within JIA-associated risk loci
por: Jiang, Kaiyu, et al.
Publicado: (2020)

MEFV mutations in systemic JIA
por: Aktay Ayaz, N, et al.
Publicado: (2008)

Mesenchymal stem cells and JIA
por: Swart, JF, et al.
Publicado: (2011)

eJIAS: Editor's Welcome
por: Wainberg, Mark A
Publicado: (2004)

The swedish paediatric JIA-registry
por: Magnusson, Bo
Publicado: (2014)

Monitoring local inflammation in JIA
por: Roth, Johannes
Publicado: (2014)

Puberty and disease activity in JIA
por: Van Pelt, Philomine, et al.
Publicado: (2014)

Clinical classification of JIA in Albania
por: Vula, Aurel, et al.
Publicado: (2014)

Progressive Pseudorheumatoid Dysplasia or JIA?
por: Wickrematilake, Geetha
Publicado: (2017)

CMS Interim Memorandum of Understanding The Costs and How They are Calculated
por: Willers, Ian Malcolm
Publicado: (2001)

Impact of a 2-yr anti-TNF treatment on the quality of life in JIA patients: a parent's/patient’s view
por: Diafa, K, et al.
Publicado: (2011)

A phase II trial protocol of Tocilizumab in anti-TNF refractory patients with JIA-associated uveitis (the APTITUDE trial)
por: Ramanan, Athimalaipet V., et al.
Publicado: (2018)

Prevention of disease flares by risk-adapted stratification of therapy withdrawal in juvenile idiopathic arthritis: results from the PREVENT-JIA trial
por: Gerss, Joachim, et al.
Publicado: (2022)

Disease characteristics and medication use in a multicenter cohort of children with juvenile idiopathic arthritis (JIA): preliminary analyses from the CARRAnet registry
por: Ringold, Sarah, et al.
Publicado: (2012)

Pediatric Rheumatology Collaborative Study Group – over four decades of pivotal clinical drug research in pediatric rheumatology
por: Brunner, Hermine I., et al.
Publicado: (2018)

Determing an “autoimmune” phenotype in systemic JIA
por: Fischer, N, et al.
Publicado: (2011)

Adverse events of methotrexate treatment in JIA
por: in ‘t Veld, J, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_m270ut5uq07rvhv4ob93qe59f6